(MedPage Today) — The FDA approved the oral estrogen receptor antagonist imlunestrant (Inluriyo) for previously treated ESR1-mutated advanced/metastatic breast cancer, the agency announced Thursday.
The approval stipulates use in adults with…
Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/117650
Author :
Publish date : 2025-09-25 21:21:00
Copyright for syndicated content belongs to the linked Source.
